Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

6.34 (USD) • At close February 5, 2025
Bedrijfsnaam Phathom Pharmaceuticals, Inc.
Symbool PHAT
Munteenheid USD
Prijs 6.34
Beurswaarde 433,512,716
Dividendpercentage 0%
52-weken bereik 5.58 - 19.71
Industrie Biotechnology
Sector Healthcare
CEO Ms. Terrie J. Curran
Website https://www.phathompharma.com

An error occurred while fetching data.

Over Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in

Vergelijkbare Aandelen

Zynex, Inc. logo

Zynex, Inc.

ZYXI

7.99 USD

LianBio logo

LianBio

LIAN

0.319 USD

Edgewise Therapeutics, Inc. logo

Edgewise Therapeutics, Inc.

EWTX

30.03 USD

Radius Health, Inc. logo

Radius Health, Inc.

RDUS

12.05 USD

Generation Bio Co. logo

Generation Bio Co.

GBIO

0.832 USD

Seres Therapeutics, Inc. logo

Seres Therapeutics, Inc.

MCRB

0.791 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)